India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of Drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »SEARCH RESULT
Total Matching Records found : 977
Road to cheaper Drugs by Rupali Mukherjee
The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper Drugs for lifestyle diseases. More generic companies could invoke the compulsory licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...
More »Congress MP B S Gnanadesikan demands surveillance of NGOs receiving foreign funds
-PTI A demand was raised in Rajya Sabha today that the Government should put in place a strong surveillance network to monitor inflow of foreign funds to NGOs besides creating a data base in the interest of national security. "Government should establish a data base of NGOs to whom foreign contribution is increasing day by day. There are reports that funds are being utilised to fuel unrest in government projects," B S...
More »AIDAN proposes another pricing model for essential Drugs by Khomba Singh
A non-government organisation campaigning for cheaper essential Drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment. The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make...
More »India's patent ruling on cancer may open door for cheaper HIV Drugs
-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS Drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...
More »
